Drug offers relief for asthma sufferers
Jeremy Laurance is a writer on health issues. He is former health editor of The Independent and the i and has covered the specialism for more than 20 years. He thinks the harm medicine does is under-appreciated, the harm it prevents over-rated, and that cycling works better than most drugs. He was named Specialist Journalist of the Year in the 2011 British Press Awards.
Monday 09 February 1998
A tablet taken once a day to prevent inflammation of the lungs may become a regular part of the treatment of asthma patients.
The drug, montelukast, is the first of a new kind of anti-asthma medicine. It is intended as an add-on treatment, to be taken with existing drugs, to reduce day and night-time attacks.
Trials of the drug, to be sold under the brand name Singulair, have shown it cuts attacks in people with moderate asthma by half when taken with inhaled steroids. It is intended for use by adults and children over six years old with chronic mild to moderate asthma whose disease is inadequately controlled.
Professor Mike Silverman, chairman of the National Asthma Campaign's education committee, said: "For some, but by no means all people with asthma, it will offer a completely new way of controlling asthma symptoms. Our main message is that tablet treatments are not going to be suitable for everybody. It is a long way off before people with the condition will be able to take a once-a-day pill instead of an inhaler."
Professor Silverman said it was too early to say which patients would benefit most. "For those whose asthma is very mild, the tablet might replace existing preventer medication, but more studies are needed before this can be recommended."
"People with asthma have always relied on inhaler devices to deliver medication to their lungs. It is essential to talk with your doctor to find out if it is going to be appropriate for you."
The new drug is targeted at leukotrienes, chemicals in the lungs that produce asthmatic symptoms by causing the muscles in the airways to tighten, the cells to produce extra mucous and the lining to become inflamed. By blocking the action of the leukotrienes, inflammation is reduced and the tubes in the lung opened up, allowing the patient to breathe more easily.
In addition to helping people with chronic asthma, the new drug will be used to help stop asthma attacks brought on by exercise.
The suffering, illness and premature death caused by air-pollution from road traffic is costing at pounds 11bn a year, according to the British Lung Foundation.
The report says one-third of the population is susceptible to the effects of pollution, including young children, pregnant women and the chronically ill. It uses a "willingness to pay" method for assessing the impact of pollution on people's lives rather than assessing only the costs of treating pollution-related health problems.
The figure of pounds 11bn is obtained by multiplying the number of pollution- related illness events (days of cough, asthma attacks, etc) and premature deaths by people's willingness to pay to avoid the risk of them happening.
Epidemic of the modern world
Three-and-a-half million people in the UK are estimated to suffer from asthma, including 1.5 million children aged 2 to 15.
In 1995, around 1,621 people in the UK died as a result of the disease - one person every five hours. Before the Sixties there werearound 100,000 cases a year and just a handful of asthma-related deaths.
Asthma is the only treatable chronic condition in the Western world which is on the increase. The number of children with the disease has doubled since the Seventies, with on average 155 admitted to hospital every day.
There were more than 100,000 hospital admissions due to asthma attacks in 1993 - a 7 per cent rise on the previous year.
Annual prescriptions for asthma treatments almost doubled in the years 1982 to 1992 with the cost of NHS treatment rocketing from pounds 50m to pounds 350m during that time.
Asthma is caused by chemicals in the body which cause airways to tighten when asthmatics come in contact with certain allergens.
As Voltaire once said, “Ice cream is exquisite. What a pity it isn’t illegal”
- 1 Mother fed her daughter tapeworms to make her skinny for beauty pageant
- 2 Crystal Palace next manager latest: Palace consider Ally McCoist - EXCLUSIVE
- 3 Richard Dawkins on babies with Down Syndrome: 'Abort it and try again – it would be immoral to bring it into the world'
- 4 ALS ice bucket challenge co-founder Corey Griffin drowns, aged 27
- 5 Tim Sherwood column: 'It started as a three-horse race but turned into the Grand National'
'Alien thigh bone' on Mars: Excitement from alien hunters at 'evidence' of extraterrestrial life
West poised to join forces with Assad in face of Islamic State
Pamela Anderson rejects ice bucket challenge because of ALS experiments on animals: 'Mice had holes drilled into their skulls'
James Foley 'beheaded': Isis video shows militant with British accent 'execute US journalist' – as hunt begins for killer
ALS ice bucket challenge co-founder Corey Griffin drowns, aged 27
Richard Dawkins on babies with Down Syndrome: 'Abort it and try again – it would be immoral to bring it into the world'
Scottish independence: English people overwhelmingly want Scotland to stay in the UK
Isis threat: Cameron wants an alliance with Iran
Michael Brown shooting: Chaos erupts on the streets of Ferguson after autopsy shows teenager was shot six times – twice in the head
Bin bag full of cats' heads discovered near Manchester's Curry Mile
Disgusting, frustrating, but intriguing: how the country really feels about its politicians
£50000 - £60000 per annum: Harrington Starr: Network Engineer - CCNP, Hedge Fu...
£60000 - £70000 per annum: Harrington Starr: Senior Network Engineer-CCIE, Mul...
£30000 - £50000 per annum: Harrington Starr: Network Infrastructure Engineer (...
£35000 - £45000 per annum: Harrington Starr: Network Engineer (CCNP, BGP, Mult...